The MoatWide moat

AbbVie (ABBV) — moat facet

AbbVie lost 79% of Humira and still grew, which proves the moat, and now depends on two drugs whose patents end in 2033.

AbbVie's moat was tested harder than almost any in the drug industry and held. Its largest product, Humira, sold $21,237 million in 20221 and $4,540 million in 20252 after American biosimilars arrived in January 20233. AbbVie's net revenues rose over the same period, from $58,054 million to $61,160 million45, because Skyrizi and Rinvoq were ready: together they sold $25,866 million in 20256.

Net revenues ($M)58,054202254,318202356,334202461,1602025AbbVie Forms 10-K FY2024 and FY2025
A dip in 2023, then a record in 2025.

That is the moat: the ability to replace a franchise before it falls, by building the successors in the same diseases and moving patients within the portfolio. It is supported by the Allergan acquisition, which added a growing neuroscience business, and by very high product margins: the adjusted gross margin was 84.7% in the second quarter of 20267.

Three things narrow it. The new franchise is as concentrated as the old one: Skyrizi and Rinvoq were about 42% of revenue in 20258, and both lose United States composition patent protection in 20339. Pricing is increasingly set by others: rebates and chargebacks were $65.1 billion in 202510, and Medicare now sets prices for four AbbVie drugs from 2026 to 202811. And the next replacement is being bought on a leveraged balance sheet, with negative equity12 and net debt of about $64 billion13.

Return on invested capital, computed from EDGAR, was 11.1% in 202514, above an assumed 8% cost of capital but far below the 28.1% of 201515.

The transition was also a management succession. Richard A. Gonzalez, chief executive since AbbVie's formation, handed over to Robert A. Michael on 1 July 202416, and Michael became chairman from 1 July 202517. The strategy did not change: maximise revenue from the key on-market products and keep buying science. The people who built the Humira replacement are the ones who must now build the next one.

The moat is wide and stable, and it now rests on the same question as before, with a later date. The number that would falsify it is the share of revenue from products protected beyond 2033; if it is still small in 2030, the company will face its next cliff with less time and less balance sheet than it had for Humira.

Moat trajectory: Holding steady

The replacement worked; concentration, pricing and leverage are the limits.

The number that tests this moat
Reported
Net revenues, latest quarter
$16,990M, +10.2% (Q2 2026)

Growth through the Humira decline; a return to decline before 2033 would mean the replacement is fading early.

Source: AbbVie Q2 2026 results release ↗
Aspects of the moat
DIG DEEPER 01
Replacing Humira Before It Fell
AbbVie lost 79% of the world's best-selling drug in three years and still grew, because it had built the replacements before the patent ran out.
DIG DEEPER 02
Pricing Power, After the Rebates
AbbVie's drugs carry very high list prices, but it gives more back in rebates than it reports as revenue, and governments are setting a growing share…
DIG DEEPER 03
Allergan: The Second Engine It Bought
The $64 billion Allergan deal gave AbbVie a growing medical Botox and neuroscience business and a shrinking cosmetics business.
DIG DEEPER 04
Buying the Next Pipeline, on a Leveraged Balance Sheet
AbbVie buys its next drugs and borrows to do it, earning about 11% on the capital, with negative equity and $64 billion of net debt.
References
  1. ReportedIts largest product, Humira, sold $21,237 million in 2022 and $4,540 million in 2025 after American biosimilars arrived in January 2023.
    AbbVie Form 10-K for fiscal 2024 - product revenue for 2022-2024, product concentration, the CEO succession and the emraclidine impairment. — FY2024 · publ. February 2025 · source ↗
  2. ReportedIts largest product, Humira, sold $21,237 million in 2022 and $4,540 million in 2025 after American biosimilars arrived in January 2023.
    AbbVie Form 10-K for fiscal 2025 - Item 7 MD&A: net revenues by product and region, and rebates. — FY2025 · publ. 20 February 2026 · source ↗
  3. ReportedIts largest product, Humira, sold $21,237 million in 2022 and $4,540 million in 2025 after American biosimilars arrived in January 2023.
    AbbVie Form 10-K for fiscal 2023 - Humira's share of revenue and US loss of exclusivity. — FY2023 · publ. February 2024 · source ↗
  4. ReportedAbbVie's net revenues rose over the same period, from $58,054 million to $61,160 million, because Skyrizi and Rinvoq were ready: together they sold $25,866 million in 2025.
    AbbVie Form 10-K for fiscal 2024 - product revenue for 2022-2024, product concentration, the CEO succession and the emraclidine impairment. — FY2024 · publ. February 2025 · source ↗
  5. ReportedAbbVie's net revenues rose over the same period, from $58,054 million to $61,160 million, because Skyrizi and Rinvoq were ready: together they sold $25,866 million in 2025.
    AbbVie Form 10-K for fiscal 2025 - Item 7 MD&A: net revenues by product and region, and rebates. — FY2025 · publ. 20 February 2026 · source ↗
  6. Moat Explorer calcAbbVie's net revenues rose over the same period, from $58,054 million to $61,160 million, because Skyrizi and Rinvoq were ready: together they sold $25,866 million in 2025.
    Moat Explorer calculation from AbbVie's reported product revenue and financial statements ($ millions unless stated). Therapeutic areas 2025: immunology 17,562 + 8,304 + 4,540 = 30,406; neuroscience 3,621 + 3,769 + 1,271 + 1,036 + 482 + 381 + 207 = 10,767; oncology 2,869 + 2,792 + 690 + 271 + 33 = 6,655; aesthetics 2,602 + 993 + 1,265 = 4,860; eye care 493 + 410 + 197 + 1,009 = 2,109; other key products 1,317 + 1,512 + 907 = 3,736; all other 2,627; eye care and other products 2,109 + 3,736 + 2,627 = 8,472; total 61,160. 2024: immunology 11,718 + 5,971 + 8,993 = 26,682; neuroscience 8,999; oncology 6,555; aesthetics 5,176; eye care and other 2,242 + 3,648 + 3,032 = 8,922. 2023: 7,763 + 3,969 + 14,404 = 26,136; neuroscience 7,717; oncology 5,915; aesthetics 5,294; eye care and other 2,415 + 3,806 + 3,035 = 9,256. 2022: 5,165 + 2,522 + 21,237 = 28,924; neuroscience 6,528; oncology 6,577; aesthetics 5,333; eye care and other 2,701 + 3,854 + 4,137 = 10,692. Growth 2025: immunology 30,406 / 26,682 - 1 = 14.0%; neuroscience 10,767 / 8,999 - 1 = 19.6%. Immunology and neuroscience 30,406 + 10,767 = 41,173, 41,173 / 61,160 = 67.3%. Immunology share 30,406 / 61,160 = 49.7%. Skyrizi + Rinvoq: 5,165 + 2,522 = 7,687 (2022); 7,763 + 3,969 = 11,732 (2023); 11,718 + 5,971 = 17,689 (2024); 17,562 + 8,304 = 25,866 (2025); H1 2026 9,988 + 4,644 = 14,632; Q2 2026 5,505 + 2,525 = 8,030, 8,030 / 16,990 = 47.3%; 2026 plan 21.5 + 10.1 = 31.6 bn. Shares of revenue 7,687 / 58,054 = 13.2%; 11,732 / 54,318 = 21.6%; 17,689 / 56,334 = 31.4%; 25,866 / 61,160 = 42.3%. Humira: 4,540 / 21,237 - 1 = -78.6%; share 8,993 / 56,334 = 16.0% (2024), 4,540 / 61,160 = 7.4% (2025). Rebates: 65.1 / 61.16 = 1.06; 65.1 / 18.8 = 3.5 times (2019-2025) against net revenues 61,160 / 33,266 = 1.8 times; gross sales 61.2 + 65.1 = 126.3 bn, 126.3 / 61.2 = 2.1 times; managed care 22,307 / 61,160 = 36.5%; Medicaid and Medicare 21,283 / 61,160 = 34.8%; payers 22,307 + 21,283 = 43,590, 43,590 / 61,160 = 71.3%. Geography: US 46,603 / 61,160 = 76.2%; international 14,557 / 61,160 = 23.8%. Gross margin 2025 (61,160 - 18,204) / 61,160 = 70.2%. Government-set price products, 2025 sales: 2,869 + 3,621 + 907 + 3,769 = 11,166, 11,166 / 61,160 = 18.3%. Goodwill and intangibles 35,640 + 52,641 = 88,281, 88,281 / 133,960 = 65.9%. Eye care share 2,109 / 61,160 = 3.4%; aesthetics share 4,860 / 61,160 = 7.9%. Net debt 30 June 2026: 62,481 + 8,341 - 6,569 = 64,253; net debt / operating cash flow 64,253 / 19,030 = 3.4 years. Free cash flow 2025: 19,030 - 1,214 = 17,816; dividends paid 11,657 / 17,816 = 65.4%; operating cash flow / dividends 19,030 / 11,657 = 1.6; dividends declared / net earnings 11,819 / 4,226 = 2.8; dividends per share 6.65 / 1.75 = 3.8 times (2014-2025). Free cash flow yield 17,816 / 468,500 = 3.8%; free cash flow per share 17,816 / 1,771 = 10.06. 2026 adjusted EPS guidance midpoints: (14.37 + 14.57) / 2 = 14.47; (13.96 + 14.16) / 2 = 14.06; (14.08 + 14.28) / 2 = 14.18; (13.91 + 14.11) / 2 = 14.01; (13.87 + 14.07) / 2 = 13.97. Ubrelvy and Qulipta Q2 2026 392 + 350 = 742; 2025 1,271 + 1,036 = 2,307. Skyrizi share 17,562 / 61,160 = 28.7%. Juvederm 993 / 1,428 - 1 = -30.5%. Aesthetics 4,860 / 5,176 - 1 = -6.1%. Gross margin 2023 (54,318 - 20,415) / 54,318 = 62.4%. Skyrizi + Rinvoq 2021 2,939 + 1,651 = 4,590; 2022 7,687 / 21,237 = 36% - therapeutic-area totals, growth and rebates. — 2015-2026 · publ. September 2026 · source ↗
    Method: Arithmetic on figures reported in AbbVie's Forms 10-K, 10-Q, results releases, the Q4 2025 call and market data; operands shown in the source line.
  7. ReportedIt is supported by the Allergan acquisition, which added a growing neuroscience business, and by very high product margins: the adjusted gross margin was 84.7% in the second quarter of 2026.
    AbbVie second-quarter 2026 results release, Form 8-K exhibit 99.1. — Q2 2026 · publ. 31 July 2026 · source ↗
  8. ReportedThe new franchise is as concentrated as the old one: Skyrizi and Rinvoq were about 42% of revenue in 2025, and both lose United States composition patent protection in 2033.
    AbbVie Form 10-K for fiscal 2025 - Item 1A risk factors, patents and exclusivity, government pricing and legal proceedings. — FY2025 · publ. 20 February 2026 · source ↗
  9. ReportedThe new franchise is as concentrated as the old one: Skyrizi and Rinvoq were about 42% of revenue in 2025, and both lose United States composition patent protection in 2033.
    AbbVie Form 10-K for fiscal 2025 - Item 1A risk factors, patents and exclusivity, government pricing and legal proceedings. — FY2025 · publ. 20 February 2026 · source ↗
  10. ReportedPricing is increasingly set by others: rebates and chargebacks were $65.1 billion in 2025, and Medicare now sets prices for four AbbVie drugs from 2026 to 2028.
    AbbVie Form 10-K for fiscal 2025 - Item 1A risk factors, patents and exclusivity, government pricing and legal proceedings. — FY2025 · publ. 20 February 2026 · source ↗
  11. ReportedPricing is increasingly set by others: rebates and chargebacks were $65.1 billion in 2025, and Medicare now sets prices for four AbbVie drugs from 2026 to 2028.
    AbbVie Form 10-K for fiscal 2025 - Item 1A risk factors, patents and exclusivity, government pricing and legal proceedings. — FY2025 · publ. 20 February 2026 · source ↗
  12. ReportedAnd the next replacement is being bought on a leveraged balance sheet, with negative equity and net debt of about $64 billion.
    AbbVie Form 10-Q for the quarter ended 30 June 2026 - product revenue, the balance sheet, cash flow and the Apogee agreement. — Q2 2026 · publ. 3 August 2026 · source ↗
  13. Moat Explorer calcAnd the next replacement is being bought on a leveraged balance sheet, with negative equity and net debt of about $64 billion.
    Moat Explorer calculation from AbbVie's reported product revenue and financial statements ($ millions unless stated). Therapeutic areas 2025: immunology 17,562 + 8,304 + 4,540 = 30,406; neuroscience 3,621 + 3,769 + 1,271 + 1,036 + 482 + 381 + 207 = 10,767; oncology 2,869 + 2,792 + 690 + 271 + 33 = 6,655; aesthetics 2,602 + 993 + 1,265 = 4,860; eye care 493 + 410 + 197 + 1,009 = 2,109; other key products 1,317 + 1,512 + 907 = 3,736; all other 2,627; eye care and other products 2,109 + 3,736 + 2,627 = 8,472; total 61,160. 2024: immunology 11,718 + 5,971 + 8,993 = 26,682; neuroscience 8,999; oncology 6,555; aesthetics 5,176; eye care and other 2,242 + 3,648 + 3,032 = 8,922. 2023: 7,763 + 3,969 + 14,404 = 26,136; neuroscience 7,717; oncology 5,915; aesthetics 5,294; eye care and other 2,415 + 3,806 + 3,035 = 9,256. 2022: 5,165 + 2,522 + 21,237 = 28,924; neuroscience 6,528; oncology 6,577; aesthetics 5,333; eye care and other 2,701 + 3,854 + 4,137 = 10,692. Growth 2025: immunology 30,406 / 26,682 - 1 = 14.0%; neuroscience 10,767 / 8,999 - 1 = 19.6%. Immunology and neuroscience 30,406 + 10,767 = 41,173, 41,173 / 61,160 = 67.3%. Immunology share 30,406 / 61,160 = 49.7%. Skyrizi + Rinvoq: 5,165 + 2,522 = 7,687 (2022); 7,763 + 3,969 = 11,732 (2023); 11,718 + 5,971 = 17,689 (2024); 17,562 + 8,304 = 25,866 (2025); H1 2026 9,988 + 4,644 = 14,632; Q2 2026 5,505 + 2,525 = 8,030, 8,030 / 16,990 = 47.3%; 2026 plan 21.5 + 10.1 = 31.6 bn. Shares of revenue 7,687 / 58,054 = 13.2%; 11,732 / 54,318 = 21.6%; 17,689 / 56,334 = 31.4%; 25,866 / 61,160 = 42.3%. Humira: 4,540 / 21,237 - 1 = -78.6%; share 8,993 / 56,334 = 16.0% (2024), 4,540 / 61,160 = 7.4% (2025). Rebates: 65.1 / 61.16 = 1.06; 65.1 / 18.8 = 3.5 times (2019-2025) against net revenues 61,160 / 33,266 = 1.8 times; gross sales 61.2 + 65.1 = 126.3 bn, 126.3 / 61.2 = 2.1 times; managed care 22,307 / 61,160 = 36.5%; Medicaid and Medicare 21,283 / 61,160 = 34.8%; payers 22,307 + 21,283 = 43,590, 43,590 / 61,160 = 71.3%. Geography: US 46,603 / 61,160 = 76.2%; international 14,557 / 61,160 = 23.8%. Gross margin 2025 (61,160 - 18,204) / 61,160 = 70.2%. Government-set price products, 2025 sales: 2,869 + 3,621 + 907 + 3,769 = 11,166, 11,166 / 61,160 = 18.3%. Goodwill and intangibles 35,640 + 52,641 = 88,281, 88,281 / 133,960 = 65.9%. Eye care share 2,109 / 61,160 = 3.4%; aesthetics share 4,860 / 61,160 = 7.9%. Net debt 30 June 2026: 62,481 + 8,341 - 6,569 = 64,253; net debt / operating cash flow 64,253 / 19,030 = 3.4 years. Free cash flow 2025: 19,030 - 1,214 = 17,816; dividends paid 11,657 / 17,816 = 65.4%; operating cash flow / dividends 19,030 / 11,657 = 1.6; dividends declared / net earnings 11,819 / 4,226 = 2.8; dividends per share 6.65 / 1.75 = 3.8 times (2014-2025). Free cash flow yield 17,816 / 468,500 = 3.8%; free cash flow per share 17,816 / 1,771 = 10.06. 2026 adjusted EPS guidance midpoints: (14.37 + 14.57) / 2 = 14.47; (13.96 + 14.16) / 2 = 14.06; (14.08 + 14.28) / 2 = 14.18; (13.91 + 14.11) / 2 = 14.01; (13.87 + 14.07) / 2 = 13.97. Ubrelvy and Qulipta Q2 2026 392 + 350 = 742; 2025 1,271 + 1,036 = 2,307. Skyrizi share 17,562 / 61,160 = 28.7%. Juvederm 993 / 1,428 - 1 = -30.5%. Aesthetics 4,860 / 5,176 - 1 = -6.1%. Gross margin 2023 (54,318 - 20,415) / 54,318 = 62.4%. Skyrizi + Rinvoq 2021 2,939 + 1,651 = 4,590; 2022 7,687 / 21,237 = 36% - balance sheet, cash flow, dividends and valuation. — 2015-2026 · publ. September 2026 · source ↗
    Method: Arithmetic on figures reported in AbbVie's Forms 10-K, 10-Q, results releases, the Q4 2025 call and market data; operands shown in the source line.
  14. Moat Explorer calcReturn on invested capital, computed from EDGAR, was 11.1% in 2025, above an assumed 8% cost of capital but far below the 28.1% of 2015.
    Moat Explorer calculation, tools_roic_edgar.py on SEC EDGAR XBRL for CIK 1551152: return on invested capital 28.1% (2015), 16.6% (2016), 13.7% (2017), 16.0% (2018), 35.5% (2019), 15.5% (2020), 14.8% (2021), 15.8% (2022), 10.8% (2023), 10.4% (2024), 11.1% (2025). — 2015-2025 · publ. September 2026 · source ↗
    Method: NOPAT (operating income x (1 - effective tax rate)) divided by average operating invested capital (total assets less current liabilities less cash), from SEC EDGAR XBRL via tools_roic_edgar.py. Operating income is after intangible amortisation and acquired IPR&D, which depresses the ratio after the Allergan acquisition.
  15. Moat Explorer calcReturn on invested capital, computed from EDGAR, was 11.1% in 2025, above an assumed 8% cost of capital but far below the 28.1% of 2015.
    Moat Explorer calculation, tools_roic_edgar.py on SEC EDGAR XBRL for CIK 1551152: return on invested capital 28.1% (2015), 16.6% (2016), 13.7% (2017), 16.0% (2018), 35.5% (2019), 15.5% (2020), 14.8% (2021), 15.8% (2022), 10.8% (2023), 10.4% (2024), 11.1% (2025). — 2015-2025 · publ. September 2026 · source ↗
    Method: NOPAT (operating income x (1 - effective tax rate)) divided by average operating invested capital (total assets less current liabilities less cash), from SEC EDGAR XBRL via tools_roic_edgar.py. Operating income is after intangible amortisation and acquired IPR&D, which depresses the ratio after the Allergan acquisition.
  16. ReportedRichard A. Gonzalez, chief executive since AbbVie's formation, handed over to Robert A. Michael on 1 July 2024, and Michael became chairman from 1 July 2025.
    AbbVie Form 10-K for fiscal 2024 - product revenue for 2022-2024, product concentration, the CEO succession and the emraclidine impairment. — FY2024 · publ. February 2025 · source ↗
  17. ReportedRichard A. Gonzalez, chief executive since AbbVie's formation, handed over to Robert A. Michael on 1 July 2024, and Michael became chairman from 1 July 2025.
    AbbVie Form 10-K for fiscal 2025 - Item 1 business: products, customers, competition and research. — FY2025 · publ. 20 February 2026 · source ↗
Sources
Generated September 25, 2026